Low-molecular-weight heparins and cancer: Focus on antitumoral effect

Massimo Franchini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.

Original languageEnglish
Pages (from-to)116-121
Number of pages6
JournalAnnals of Medicine
Volume47
Issue number2
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Low Molecular Weight Heparin
Venous Thromboembolism
Neoplasms
Fibrinolytic Agents
Survival
Thrombosis
Clinical Trials
Safety

Keywords

  • Cancer
  • Low-molecular-weight heparin
  • Prophylaxis
  • Survival
  • Therapy
  • Venous thromboembolism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Low-molecular-weight heparins and cancer : Focus on antitumoral effect. / Franchini, Massimo; Mannucci, Pier Mannuccio.

In: Annals of Medicine, Vol. 47, No. 2, 01.03.2015, p. 116-121.

Research output: Contribution to journalArticle

@article{49d04e1dec344e6fbc9b1f7ba5bef420,
title = "Low-molecular-weight heparins and cancer: Focus on antitumoral effect",
abstract = "A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.",
keywords = "Cancer, Low-molecular-weight heparin, Prophylaxis, Survival, Therapy, Venous thromboembolism",
author = "Massimo Franchini and Mannucci, {Pier Mannuccio}",
year = "2015",
month = "3",
day = "1",
doi = "10.3109/07853890.2015.1004361",
language = "English",
volume = "47",
pages = "116--121",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Low-molecular-weight heparins and cancer

T2 - Focus on antitumoral effect

AU - Franchini, Massimo

AU - Mannucci, Pier Mannuccio

PY - 2015/3/1

Y1 - 2015/3/1

N2 - A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.

AB - A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.

KW - Cancer

KW - Low-molecular-weight heparin

KW - Prophylaxis

KW - Survival

KW - Therapy

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84928103842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928103842&partnerID=8YFLogxK

U2 - 10.3109/07853890.2015.1004361

DO - 10.3109/07853890.2015.1004361

M3 - Article

C2 - 25766973

AN - SCOPUS:84928103842

VL - 47

SP - 116

EP - 121

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 2

ER -